Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Guardant Health Inc
(NQ:
GH
)
21.34
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
49
Open
21.34
Bid (Size)
20.59 (1)
Ask (Size)
21.93 (1)
Prev. Close
21.34
Today's Range
21.34 - 21.34
52wk Range
15.81 - 37.04
Shares Outstanding
101,298,669
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test
October 04, 2024
Exact Sciences' Cologuard Plus test, now FDA-approved, offers a non-invasive screening option for adults 45+ at average risk for colorectal cancer. The test outperformed fecal immunochemical tests in...
Via
Benzinga
Exposures
Product Safety
GOZILA Study Published in Nature Medicine Shows Patients With Advanced Cancer Who Receive Liquid Biopsy-Guided Treatment Using Guardant360 CDx Survive Twice as Long
September 18, 2024
From
Guardant Health, Inc.
Via
Business Wire
Performance
YTD
-19.50%
-19.50%
1 Month
-15.92%
-15.92%
3 Month
-32.34%
-32.34%
6 Month
+25.09%
+25.09%
1 Year
-22.77%
-22.77%
More News
Read More
Sky Harbour Group, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
September 17, 2024
Via
Benzinga
iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
September 16, 2024
Via
Benzinga
Key Takeaways From Guardant Health Analyst Ratings
August 08, 2024
Via
Benzinga
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
September 16, 2024
Via
Benzinga
Guardant Health to Share Data at ESMO 2024 Further Demonstrating Strong Performance of Its Precision Oncology Technology in Multiple Advanced Tumor Types
September 13, 2024
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health and Policlinico Gemelli Announce Partnership to Establish A Dedicated In-House Liquid Biopsy Testing Service in Italy
September 10, 2024
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 27, 2024
From
Guardant Health, Inc.
Via
Business Wire
Why Guardant Health Stock Just Crashed 10%
August 26, 2024
Via
The Motley Fool
PDD Holdings, Daqo New Energy And Other Big Stocks Moving Lower In Monday's Pre-Market Session
August 26, 2024
Via
Benzinga
Sector Spotlight: Top 4 Basket of Diagnostic Stocks (EXAS, GH, ILMN, LUDG)
August 23, 2024
Via
AB Newswire
Exposures
COVID-19
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
August 23, 2024
Via
The Motley Fool
Guardant Health to Ring the Nasdaq Opening Bell on August 28 to Celebrate the Launch of Shield™ Blood Test for Colorectal Cancer Screening
August 22, 2024
From
Guardant Health, Inc.
Via
Business Wire
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
August 12, 2024
Via
The Motley Fool
Cathie Wood's Ark Invest Continues Loads Up On $6.05M Worth Of Robinhood Shares Amid Bitcoin Rebound, Dumps Zoom Stock
August 08, 2024
Via
Benzinga
Guardant Health to Participate in Upcoming Investor Conferences
August 08, 2024
From
Guardant Health, Inc.
Via
Business Wire
GH Stock Earnings: Guardant Health Beats EPS, Beats Revenue for Q2 2024
August 07, 2024
Via
InvestorPlace
Guardant Health Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
August 07, 2024
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health COSMOS Study Published in Clinical Cancer Research Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Colorectal Cancer
August 07, 2024
From
Guardant Health, Inc.
Via
Business Wire
Why Exact Sciences, Up 20%, Is 'Coiled To Snap Back' After Quarterly Beat
August 01, 2024
Via
Investor's Business Daily
Guardant Health’s FDA-approved Shield™ Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer
August 01, 2024
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Outcomes Model Confirms the Public Health Importance of Enhanced Colorectal Cancer Screening Outcomes with High Adherence Strategies
August 01, 2024
From
Guardant Health, Inc.
Via
Business Wire
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
July 31, 2024
Via
The Motley Fool
FDA Greenlights Guardant Health's Shield Blood Test, Analyst Cautious on Adoption
July 29, 2024
Via
Benzinga
Exposures
Product Safety
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.